Wendy's said on Thursday that it is rejecting a $1.4 billion takeover offer from a group led by Nelson Peltz's Trian Fund Management. The group offered $7.35 per share in cash on Oct. 28 to take the struggling burger chain private. Its board's independent committee concluded that the proposal "substantially undervalues" the company and does not reflect potential gains from its ongoing turnaround strategy. On the narrow question of price, that conclusion deserves respect.

The timing and the history matter too. Trian is not a stranger to Wendy's. Peltz led an activist campaign at the chain more than two decades ago, and his firm Triarc bought Wendy's in a $2.3 billion deal in 2008 before later selling Arby's and returning Wendy's to stand-alone status. Peltz was named chairman emeritus in 2024 after 17 years on the board, and Trian executive Peter May and Bradley Peltz still sit on the board. An offer from a group with that much familiarity should face hard questions about whether it is aimed at value or at control.

Wendy's own numbers show why skepticism is warranted. Same-store sales have declined for seven straight quarters, and the stock has lost about 60% of its value over the last three years. Yet the company reported third-quarter earnings and revenue above Wall Street's expectations, and the takeover bid had lifted the shares. Those mixed signals suggest a business that is struggling but not finished. Board chair Art Winkleblack pointed to the "proven track record" of CEO Bob Wright in restaurant turnarounds, a claim that will now be tested in public rather than in a private negotiation.

The board's defensive moves deserve closer scrutiny. Wendy's adopted a one-year shareholder rights plan, commonly called a poison pill, and it said the Trian-led group had rejected a standstill agreement that would have paused additional share purchases. A poison pill can protect shareholders from a coercive bid, but it can also entrench management and make it harder for owners to weigh a premium. The board should be clear about the specific gains it expects from its turnaround and set measurable goals for the coming year.

My recommendation is simple. Wendy's should publish concrete benchmarks for same-store sales and margin recovery, and it should explain how those benchmarks compare with the $7.35 offer. If the turnaround fails to show progress within the year, shareholders will be entitled to ask why they were asked to trust management over a buyer. Rejecting a low bid is defensible. Rejecting accountability is not.